4/A: Robert Nelsen Corrects Stock Option Acquisition in Amended SEC Filing

Robert Nelsen, a director and 10% owner of Sana Biotechnology, Inc., files an amended Form 4 to correct the number of option shares acquired on June 6, 2024.

Summary

• Robert Nelsen, a director and 10% owner of Sana Biotechnology, Inc., filed an amended Form 4/A with the SEC.
• The amendment corrects a clerical error regarding the number of option shares acquired on June 6, 2024.
• Nelsen acquired 65,000 stock options with an exercise price of $7.36.
• The options vest and become exercisable as to 100% of the underlying shares on the earlier of June 6, 2025, or immediately prior to the 2025 annual meeting of Sana Biotechnology, Inc., provided continuous service is maintained.
• Following the transaction, Nelsen beneficially owns 65,000 derivative securities.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing correcting a clerical error. It doesn't indicate any significant positive or negative developments for the company, but transparency is generally viewed favorably.

Industry Context

This filing is a routine disclosure related to insider transactions and is common for publicly traded companies. It provides transparency into the holdings and transactions of company insiders.

Stakeholder Impact

• The correction of the clerical error ensures accurate information for shareholders regarding insider ownership.

Key Dates